Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. | Resmed believes ...
Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced ...
Air Voel, one of Canada’s leading providers of CPAP machines, masks, and sleep-health solutions, today announced the launch of its Sleep Better 2026 Initiative, a nationwide program designed to raise ...
Gift 5 articles to anyone you choose each month when you subscribe. Sleep apnea device maker ResMed will expand its American manufacturing operations and open a new facility in Indianapolis in 2027 ...
This sleep disorder treatment company delivered more strong growth during the three months. ResMed posted a 9% revenue increase and an 11% rise in net income for the September quarter, driven by ...
KeyBanc analyst Brett Fishbin maintained a Buy rating on Resmed today. The company’s shares closed yesterday at $272.60. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...
ResMed plans to sign a lease for an about 446,500-square-foot building on Collins Road in Greenwood. The company is seeking a nearly $500,000 three-year tax break from the Greenwood City Council.
Thinking about using a CPAP machine to quell sleep apnea? It's not necessarily a good idea for everyone, a new evidence review argues. This common treatment for sleep apnea might increase some folks' ...
Powered by rising margins, global growth, and confidence from management, this sleep tech stock is turning heads again. The New York Stock Exchange-listed ResMed Inc (NYSE: RMD) share price surged ...
Gift 5 articles to anyone you choose each month when you subscribe. Resmed has beaten full-year earnings and revenue forecasts on the back of strong global sales of its devices to treat sleep apnoea, ...
Revenue: $1.35 billion, a 10% increase year-over-year. Gross Margin: 61.4%, an expansion of 230 basis points year-over-year. Free Cash Flow: $1.7 billion for fiscal year 2025. Net Income: Increased by ...
RBC Capital analyst Craig Wong-Pan upgraded Resmed to a Buy today and set a price target of $294.00. The company’s shares opened today at $258.85. According to TipRanks, Wong-Pan is an analyst with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback